Abstract: Disclosed is a method for preparing hydrogen-rich fuel gas, including adding aluminum smelting waste residues into medium strong acid and soaking for 2-4 h, filtering and baking an obtained precipitate at 300-400° C. for 3-6 h to obtain pre-treated aluminum smelting waste residues; adding the waste residues into weak acid and performing ultrasonic treatment, performing centrifugal separation on an aluminum ash solution, baking for 3-6 h at a constant temperature of 400-500° C. in an air atmosphere, and naturally cooling to room temperature to obtain a cracking catalyst; uniformly mixing the cracking catalyst and biomass with a mass ratio of 1:1 and adding into a first-stage pyrolyzing furnace under N2 atmosphere, and heating from room temperature to 500-900° C. to obtain first-stage pyrolysis gas; and entering the first-stage pyrolysis gas into a second-stage pyrolyzing furnace for secondary catalytic cracking, so as to obtain hydrogen-rich fuel gas.

Abstract: Provided are an anti-B7-H4 antibody-drug conjugate and medicinal use thereof. Specifically, provided is an anti-B7-H4 antibody or antigen-binding fragment thereof, a humanized antibody comprising the CDR region of the anti-B7-H4 antibody, and antibody-drug conjugate thereof or pharmaceutically acceptable salt or solvent compound thereof, and the aforesaid antibody-drug conjugate thereof or pharmaceutical composition of a pharmaceutically acceptable salt or solvent compound thereof, and use thereof as an anti-cancer drug, particularly the use in the preparation of a drug for treating diseases or disorders having high expression of B7-H4.

Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.

Abstract: An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.